Loading...
Market
Story
Amgen Receives Accelerated FDA Approval for New Lung Cancer Drug Imdelltra
May 16, 2024, 07:45 PM
Amgen has received accelerated approval from the U.S. Food and Drug Administration (FDA) on Thursday for its new drug, Imdelltra (tarlatamab), designed to treat adult patients with advanced small cell lung cancer (SCLC). This approval is specifically for patients whose disease has progressed despite chemotherapy. Imdelltra is a DLL3-targeting bispecific T-cell engager and represents a significant advancement in the treatment of this aggressive and most deadly form of lung cancer.
View original story
Similar markets
Approved in EU • 25%
Approved in Asia • 25%
Approved in LATAM • 25%
Not approved in other regions • 25%
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
Adopted in over 20 countries • 25%
Adopted in 10-20 countries • 25%
Adopted in less than 10 countries • 25%
Not adopted as standard treatment • 25%
Top performer • 33%
Average performer • 34%
Underperformer • 33%
Increase by less than 5% • 25%
Increase by 5% to 10% • 25%
Increase by 10% to 20% • 25%
Increase by more than 20% • 25%
Significant increase • 25%
Moderate increase • 25%
No significant impact • 25%
Decrease due to other factors • 25%